Thymulin

Thymulin is a real hormone with an unusual property: a zinc ion sits inside the molecule and the peptide has no biological activity without it. Not a cofactor somewhere else in a pathway, part of the active hormone itself.

That property shapes everything about the evidence. There is good human research here, in good journals, and it is about zinc rather than about the peptide. Nobody has run a study giving thymulin to a person. The randomised human trials that surface when people search this compound belong to three other thymic preparations, one of which already has its own entry in this library.

Thymulin is a chain of nine amino acids produced by the epithelial cells of the thymus, described in the early 1970s under the name facteur thymique serique. It circulates, and its measured activity declines as the thymus shrinks with age.

The zinc is what makes it distinctive. The peptide and the zinc together form the active hormone, and both the biological activity and the immune recognition of the molecule depend on the metal being there. A consequence follows immediately and is easy to miss: a thymulin measurement reads out two things at once, how much peptide is present and how much zinc is available to activate it. Most of the human literature turns on exactly that ambiguity.

Where the Biology Gets Interesting

The thymus is where T cells learn to be T cells, and it is one of the few organs that is supposed to shrink over a lifetime. Thymulin is one of the signals it produces while it is working, and it drives differentiation of T cells both inside the thymus and outside it.

That places it in a genuinely interesting position, at the junction between an endocrine organ and the immune system, and in an axis that also connects to pituitary signalling. It is also why the compound is marketed the way it is. An organ that declines with age, a hormone that declines with it, and a peptide available to buy is a persuasive sequence. Whether the last step follows from the first two is the question the evidence has to answer, and on this compound it has not been asked in humans.

The Mechanism, Without Overstating It

The peptide binds zinc, and the zinc-bound form is the active hormone. Remove the metal and the same nine amino acids are still there and do nothing. This was established by the group that originally characterised the molecule and has held since.

The downstream account is induction of T-cell differentiation, with a described role in the axis linking the thymus to neuroendocrine signalling. In animal work the molecule and a synthetic analogue of it also show anti-inflammatory and pain-modulating effects.

The zinc dependence has a consequence worth stating clearly, because it explains why the human literature looks the way it does. If a person's measured thymulin activity is low, that can mean the thymus is producing less peptide, or it can mean there is not enough zinc to activate what is produced. Those are different problems with different answers, and only one of them was ever tested in people.

The overreach on thymulin is unusually specific, and it is mostly a naming problem.

The first error is accepting the trial list. Thymostimulin, thymomodulin and thymosin alpha-1 all have real randomised human trials. None of them is thymulin. Thymosin alpha-1 in particular has its own entry in this library, is a different length, a different molecule, and carries an evidence base thymulin does not share.

The second is treating a marker as an intervention. Thymulin activity is a useful measurement, and what the human studies showed is that correcting zinc raises it. That is evidence about zinc.

The third is the confound built into the measurement itself. Because activity depends on both peptide and metal, a low reading does not identify which is short, and supplying the peptide from outside has never been shown in a person to address either.

The fourth is reading the age-related decline as a target. Thymulin activity falls as the thymus involutes, which is an observation about ageing rather than a demonstration that raising it changes anything.

There is no human safety record for thymulin, and the reason is simple: no human study has given it to anyone. Nothing can be said about tolerance, adverse effects, or what happens over any period, and an absent record is not a reassuring one. The animal work has not been carried into a human safety study either.

The regulatory picture is more informative than usual. Thymulin acetate appears in Category 3 of the FDA's 503A nominations, which means it was put forward for the compounding list with insufficient supporting information for the agency to evaluate it. Category 3 substances do not receive the enforcement policy that applies to Category 1, and FDA states it would consider action against a compounder using them. A regulator arriving independently at the same conclusion the evidence review reaches is worth noticing.

There is no approved thymulin product anywhere, so material sold outside a research setting carries the usual identity and purity questions with nothing to compare it against. On anti-doping, thymulin is not named on the 2026 Prohibited List, which is not permission: S0 prohibits at all times any substance with no current approval by any regulator for human therapeutic use.

Read honestly, this entry supports a short set of statements. Thymulin is a genuine thymic hormone whose activity requires zinc. In people, measured thymulin activity falls when zinc status is low and rises when zinc status is corrected, which has been shown in experimentally induced deficiency and in a clinical population. In animals, the molecule and an analogue of it show anti-inflammatory and pain-modulating effects.

What follows for a reader is narrower than the marketing suggests and more interesting than nothing. The measurement is a window onto zinc status. The intervention with human evidence behind it, in these studies, was zinc rather than the peptide. And the thymic peptide with an actual human trial record is a different molecule with its own page. None of that is advice about what anyone should take; it is a description of which questions have been answered and which have not.

Not thymosin alpha-1. That is a separate twenty-eight-residue synthetic peptide with its own human trial record and its own entry in this library, and the two are routinely discussed as though the evidence were shared.

Not the substance in the thymic extract trials. Thymostimulin and thymomodulin are preparations made from bovine and calf thymus tissue, and the randomised trials attached to those names are not trials of this nonapeptide.

Not studied as an administered peptide in people. Every human study cited here measured thymulin in blood or supplied zinc; none gave thymulin to anyone, so there is no human efficacy or safety record to draw on.

Not interchangeable with the zinc finding. The human research showed that correcting zinc raises measured thymulin activity, which is evidence about zinc status and not evidence that supplying the peptide from outside does anything comparable.

Not a protocol or personal-use guide. This is largely older immunology research about a zinc-dependent thymic peptide, and it explains why the compound is studied without establishing anything about giving it to a person.

Thymulin has the most elegant mechanism in this expansion set and one of the thinnest cases for buying it, which is a combination worth being able to recognise. A hormone whose activity is switched by a trace metal is a genuinely good piece of biology, and the human studies built on it are careful work.

They just answer a different question. What they establish is that thymulin activity tracks zinc status in people. What is sold is the peptide, on the strength of trials that belong to bovine thymus extracts and to a different synthetic peptide entirely. This is not the first compound in this library whose evidence turns out to belong to a neighbour, and by now that pattern is the thing worth teaching. Before accepting any claim about a peptide, the first question is not how strong the study was. It is which molecule the study used.